ADPT analyst estimates

Adaptive Bio (ADPT) analyst ratings, the average price target and its range, and every firm's latest call.

ADPT analyst ratings and price targets

DateFirmCallTarget
Oct 12, 2026Morgan StanleyAdaptive Biotechnologies price target raised to $27 from $22 at Morgan Stanley$27.00
Oct 1, 2026GuggenheimAdaptive Biotechnologies price target raised to $32 from $25 at Guggenheim$32.00
Sep 29, 2026Goldman SachsGoldman Sachs Starts Adeptus Biotechnologies Corp. (ADPT) at Buy$35.00
Sep 22, 2026National BankAdaptive Biotechnologies price target raised to $34 from $25 at BTIG$34.00
Sep 21, 2026BTIGAdeptus Biotechnologies Corp. (ADPT) PT Raised to $34 at BTIGMember Login$34.00
Aug 4, 2026Piper SandlerAdaptive Biotechnologies price target raised to $27.50 from $20 at Piper Sandler$27.50
Jul 30, 2026BTIGAdeptus Biotechnologies Corp. (ADPT) PT Raised to $25 at BTIG$25.00
Jul 30, 2026GuggenheimAdaptive Biotechnologies price target raised to $25 from $22 at Guggenheim$25.00
Jul 9, 2026Morgan StanleyAdaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley$20.00
Jun 29, 2026GuggenheimAdaptive Biotechnologies price target raised to $22 from $21 at Guggenheim$22.00
Feb 6, 2026Piper SandlerAdaptive Biotechnologies price target raised to $21 from $20 at JPMorgan$21.00
Feb 6, 2026BTIGAdaptive Biotechnologies price target raised to $22 from $21 at BTIG$22.00
Jan 26, 2026GuggenheimAdaptive Biotechnologies price target raised to $21 from $20 at Guggenheim$21.00
Dec 1, 2025Morgan StanleyAdaptive Biotechnologies assumed with an Equal Weight at Morgan Stanley$21.00
Oct 15, 2025Piper SandlerAdaptive Biotechnologies price target raised to $20 from $15 at Piper Sandler$20.00

Updated 2026-11-02 23:59 UTC